Iboctadekin

Iboctadekin
Trade Name
Orphan Indication Renal cancer
USA Market Approval USA
USA Designation Date 2005-06-03 00:00:00
Sponsor GlaxoSmithKline LLC;Corporation service Company, Suite 400;Wilmington, Delaware, 19808